Pay in 4 interest-free payments of $5.29 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
MedicalDaily Evidence Check Study type: Phase 3 randomized controlled trial (ATTAIN program) Participants: Adults with obesity or overweight with at least one weight-related comorbidity Approval date: April 1, 2026 What it found: Average weight loss of approximately 12.4% (about 27 lbs) at highest dose over 72 weeks What it did not prove: That it matches injectable GLP-1 efficacy
PubMed PMID: 39064070
When the medication is stopped, most patients regain a significant portion of the weight they lost
Helps maintain healthy blood pressure by reducing fluid volume
Avoid antacids within 2 hours to avoid negative interactions
US$ 25.57
US$ 20.56
US$ 25.45
US$ 27.19
US$ 20.52
